Associated Papers
Whole-exome profiles of inflammatory breast cancer and pathological response to neoadjuvant chemotherapy.
Bertucci F et al.
Journal of Translational Medicine, 2024
39465437 (PubMed )
Supplement: 12967_2024_5790_MOESM2_ESM.xlsx › Table_S2
Mutational landscape of inflammatory breast cancer.
Bertucci F et al.
Journal of Translational Medicine, 2024
38637846 (PubMed )
Supplement: 12967_2024_5198_MOESM2_ESM.xlsx › Table_S2
Establishment and validation of preclinical models of SMARCA4-inactivated and ARID1A/ARID1B co-inactivated dedifferentiated endometrial carcinoma.
Wong NKY et al.
Gynecologic Oncology, 2023
Pembrolizumab and Trastuzumab in High Tumor Mutational Burden and POLE-Mutated HER2-Positive Refractory Breast Cancer.
Zhang L et al.
The Oncologist, 2022
A CRISPR/Cas9 Functional Screen Identifies Rare Tumor Suppressors.
Katigbak A et al.
Scientific Reports, 2016
27982060 (PubMed )
Supplement: srep38968-s2.xls › Sheet1
VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research.
Lai Z et al.
Nucleic Acids Research, 2016
27060149 (PubMed )
Supplement: gkw227_Supplementary_Data.zip › nar-03544-met-k-2015-File003.xls › Suppl._Table_3
Select a paper to view details